Citadel Advisors’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.4M | Buy |
271,283
+45,940
| +20% | +$406K | ﹤0.01% | 2529 |
|
|
2025
Q1 | $2.35M | Buy |
225,343
+37,606
| +20% | +$392K | ﹤0.01% | 2444 |
|
|
2024
Q4 | $2.32M | Buy |
187,737
+187,648
| +210,840% | +$2.31M | ﹤0.01% | 2454 |
|
|
2024
Q3 | $2.45K | Sell |
89
-13,697
| -99% | -$377K | ﹤0.01% | 5565 |
|
|
2024
Q2 | $400K | Sell |
13,786
-25,531
| -65% | -$740K | ﹤0.01% | 4024 |
|
|
2024
Q1 | $1.75M | Sell |
39,317
-134,544
| -77% | -$6M | ﹤0.01% | 2617 |
|
|
2023
Q4 | $6.75M | Buy |
173,861
+136,504
| +365% | +$5.3M | ﹤0.01% | 1466 |
|
|
2023
Q3 | $1.1M | Buy |
37,357
+35,321
| +1,735% | +$1.04M | ﹤0.01% | 2949 |
|
|
2023
Q2 | $130K | Sell |
2,036
-925
| -31% | -$58.8K | ﹤0.01% | 4636 |
|
|
2023
Q1 | $140K | Buy |
2,961
+2,107
| +247% | +$99.5K | ﹤0.01% | 4783 |
|
|
2022
Q4 | $59.2K | Buy |
+854
| New | +$59.2K | ﹤0.01% | 5220 |
|
|
2022
Q2 | – | Sell |
-12,452
| Closed | -$1.26M | – | 6555 |
|
|
2022
Q1 | $1.26M | Sell |
12,452
-4,683
| -27% | -$473K | ﹤0.01% | 3517 |
|
|
2021
Q4 | $2.65M | Buy |
17,135
+7,749
| +83% | +$1.2M | ﹤0.01% | 2737 |
|
|
2021
Q3 | $2.78M | Sell |
9,386
-7,016
| -43% | -$2.08M | ﹤0.01% | 2640 |
|
|
2021
Q2 | $5.33M | Buy |
+16,402
| New | +$5.33M | ﹤0.01% | 2078 |
|